20 June 2013
Keywords: fda, approves, 30-min, onset, novartis, focalin, xr
Article | 01 December 2008
The US Food and Drug Administration has approved a 30-minute onset of action for Swiss drug major Novartis' Focalin XR ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 December 2008
24 November 2008
19 June 2013
© 2013 thepharmaletter.com